Slawomir Jeka

Ujejski St. 75
Bydgoszcz, KP 85168, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Journal: Clinical drug investigation

Published: May 28, 2025

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary.

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary.

Journal: Immunotherapy

Published: May 12, 2025

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health.

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health.

Journal: Therapeutic advances in musculoskeletal disease

Published: October 18, 2024

Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment.

Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment.

Journal: Archivum immunologiae et therapiae experimentalis

Published: June 28, 2024

Environmental and Genetic Determinants of Ankylosing Spondylitis.

Environmental and Genetic Determinants of Ankylosing Spondylitis.

Journal: International journal of molecular sciences

Published: June 19, 2024

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.

Journal: RMD open

Published: May 10, 2024

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).

Journal: Arthritis research & therapy

Published: February 20, 2024

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.

Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.

Journal: Rheumatology and therapy

Published: December 16, 2023

Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.

Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: November 06, 2023

Association of MICA and NKG2D genetic variants with disease susceptibility and outcome of anti-TNF therapy in patients with axial spondyloarthritis.

Association of MICA and NKG2D genetic variants with disease susceptibility and outcome of anti-TNF therapy in patients with axial spondyloarthritis.

Journal: Clinical and experimental rheumatology

Published: September 20, 2023

Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.

Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.

Journal: Advances in therapy

Published: June 22, 2023

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.

Journal: Annals of the rheumatic diseases

Published: June 16, 2023

Showing 1-12 of 71

Last Updated: 09/26/2026